SCHEMBL4170903

SCHEMBL4170903

CCNc1nc(C)c(-c2ccnc(Nc3cccc(S(=O)(=O)NC(C)OC)c3)n2)s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 18/20 0.61
CDK9 P50750 14/20 0.61
CDK7 P50613 12/20 0.61
CDK1 P06493 11/20 0.61
CCNT1 O60563 9/20 0.61
CCNA2 P20248 9/20 0.61
CCNB1 P14635 8/20 0.61
CCNH P51946 8/20 0.61
CCNA1 P78396 7/20 0.61
AURKA O14965 5/20 0.57
AURKB Q96GD4 5/20 0.57
CDK4 P11802 9/20 0.51
WEE1 P30291 2/20 0.48
FLT3 P36888 2/20 0.48
ALK Q9UM73 2/20 0.48
CHEK1 O14757 1/20 0.47
DAPK3 O43293 1/20 0.47
JAK2 O60674 1/20 0.47
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4162483 0.92 CDK2 (0.65) CDK2CDK9CDK7CDK1CCNT1
SCHEMBL4162469 0.87 CDK2 (0.70) CDK2CDK9CDK7CDK1CCNT1
SCHEMBL4166861 0.87 CDK2 (0.68) CDK2CDK9CDK7CDK1CCNT1
SCHEMBL4158541 0.85 CDK2 (0.63) CDK2CDK9CDK7CDK1CCNT1
SCHEMBL4163369 0.85 CDK2 (0.67) CDK2CDK9CDK7CDK1CCNT1
SCHEMBL4166874 0.84 CDK2 (0.81) CDK2CDK9CDK7CDK1CCNT1
SCHEMBL4156573 0.84 CDK2 (0.64) CDK2CDK9CDK7CDK1CCNT1
SCHEMBL4158525 0.83 CDK2 (0.62) CDK2CDK9CDK7CDK1CCNT1
SCHEMBL4159991 0.82 CDK2 (0.61) CDK2CDK9CDK7CDK1CCNT1
SCHEMBL27684380 0.81 CDK2 (0.60) CDK2CDK9CDK7CDK1CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 CDK2 1/4885CDK9 34/4885CDK7 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.